Interleukin-18 and testosterone levels in men with metabolic syndrome

References

• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol. 2005;4:198–203.
   PubMedGoogle Scholar
• Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012;15:635–645.
   PubMed Web of Science ®Google Scholar
• Arivazhagan J, Nandeesha H, Dorairajan LN, et al. Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia. Aging Male. 2017;20:115–118.
   PubMed Web of Science ®Google Scholar
• Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995;378:88–91.
   PubMed Web of Science ®Google Scholar
• Garcia VE, Uyemura K, Sieling PA, et al. IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection. J Immunol. 1999;162:6114–6121.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol. 2007;27:98–114.
   PubMed Web of Science ®Google Scholar
• Fain JN, Tichansky DS, Madan AK. Most of the interleukin 1 receptor antagonist, cathepsin S, macrophage migration inhibitory factor, nerve growth factor, and interleukin 18 release by explants of human adipose tissue is by the non-fat cells, not by the adipocytes. Metab Clin Exp. 2006;55:1113–1121.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr. 2006;83:447S–455S.
   PubMed Web of Science ®Google Scholar
• Novick D, Schwartsburd B, Pinkus R, et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine. 2001;14:334–342.
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Yoshimoto T, Tsutsui H, et al. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001;12:53–72.
   PubMed Web of Science ®Google Scholar
• Hung J, McQuillan BM, Chapman CM, et al. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol. 2005;25:1268–1273.
   PubMed Web of Science ®Google Scholar
• Bruun JM, Stallknecht B, Helge JW, et al. Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol. 2007;157:465–471.
   PubMed Web of Science ®Google Scholar
• Bosch M, Lopez-Bermejo A, Vendrell J, et al. Circulating IL-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass. Diabetologia. 2005;48:1841–1843.
   PubMed Web of Science ®Google Scholar
• Fischer CP, Perstrup LB, Berntsen A, et al. Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol. 2005;117:152–160.
   PubMed Web of Science ®Google Scholar
• Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med. 2009;6:192–199.
   PubMedGoogle Scholar
• Evans J, Collins M, Jennings C, et al. The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur J Endocrinol. 2007;157:633–640.
   PubMed Web of Science ®Google Scholar
• Van Guilder GP, Hoetzer GL, Greiner JJ, et al. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity. 2006;14:2127–2131.
   PubMed Web of Science ®Google Scholar
• Zirlik A, Abdullah SM, Gerdes N, et al. Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:2043–2049.
   PubMed Web of Science ®Google Scholar
• Netea MG, Joosten LA, Lewis E, et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med. 2006;12:650–656.
   PubMed Web of Science ®Google Scholar
• Zilverschoon GR, Tack CJ, Joosten LA, et al. Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. Int J Obes (Lond). 2008;32:1407–1414.
   PubMed Web of Science ®Google Scholar
• Delamaire M, Maugendre D, Moreno M, et al. Impaired leucocyte functions in diabetic patients. Diabet Med. 1997;14:29–34.
   PubMed Web of Science ®Google Scholar
• Gallacher SJ, Thomson G, Fraser WD, et al. Neutrophil bactericidal function in diabetes mellitus: evidence for association with blood glucose control. Diabet Med. 1995;12:916–920.
   PubMed Web of Science ®Google Scholar
• Zorrilla EP, Sanchez-Alavez M, Sugama S, et al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc Natl Acad Sci USA. 2007;104:11097–11102.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5–15.
   PubMed Web of Science ®Google Scholar
• Allen NE, Appleby PN, Davey GK, et al. Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control. 2002;13:353–363.
   PubMed Web of Science ®Google Scholar
• Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes. 2007;14:226–234.
   PubMedGoogle Scholar
• Kupelian V, Page ST, Araujo AB, et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91:843–850.
   PubMed Web of Science ®Google Scholar
• Muller M, Grobbee DE, den Tonkelaar I, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90:2618–2623.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Meehan AG, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?. J Urol. 2006;176:1524–1527. discussion 1527–1528.
   Web of Science ®Google Scholar
• Guay AT. The emerging link between hypogonadism and metabolic syndrome. J Androl. 2009;30:370–376.
   PubMedGoogle Scholar
• Rodriguez A, Muller DC, Metter EJ, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab. 2007;92:3568–3572.
   PubMed Web of Science ®Google Scholar
• Maggio M, Ceda GP, Lauretani F, et al. Gonadal status and physical performance in older men. Aging Male. 2011;14:42–47.
   PubMed Web of Science ®Google Scholar
• Yu XH, Zhao J, Zhang SC, et al. The impact of age, BMI and sex hormone on aging males' symptoms and the international index of erectile function scores. Aging Male. 2017;20:235–240.
   PubMed Web of Science ®Google Scholar
• Panach-Navarrete J, Martinez-Jabaloyas JM, DE-SDT study group. The influence of comorbidities on the aging males' symptoms scale in patients with erectile dysfunction. Aging Male. 2017;20:146–152.
   PubMed Web of Science ®Google Scholar
• Almehmadi Y, Yassin DJ, Yassin AA. Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism. Aging Male. 2015;18:186–194.
   PubMed Web of Science ®Google Scholar
• Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009;12:29–34.
   PubMed Web of Science ®Google Scholar
• Kaya E, Sikka SC, Kadowitz PJ, et al. Aging and sexual health: getting to the problem. Aging Male. 2017;20:65–80.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366:1059–1062.
   PubMed Web of Science ®Google Scholar
• Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762–769.
   PubMed Web of Science ®Google Scholar
• Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metab Clin Exp. 2000;49:1239–1242.
   PubMed Web of Science ®Google Scholar
• Heinemann LAJZT, Vermeulen A, Thiel C. A new ‘Aging Male’s Symptoms’ (AMS) Rating Scale. Aging Male. 1999;2:105–114.
   Google Scholar
• Ghayur T, Banerjee S, Hugunin M, et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature. 1997;386:619–623.
   PubMed Web of Science ®Google Scholar
• Troseid M, Seljeflot I, Weiss TW, et al. Arterial stiffness is independently associated with interleukin-18 and components of the metabolic syndrome. Atherosclerosis. 2010;209:337–339.
   PubMed Web of Science ®Google Scholar
• Olusi SO, Al-Awadhi A, Abraham M. Relations of serum interleukin 18 levels to serum lipid and glucose concentrations in an apparently healthy adult population. Horm Res Paediatr. 2003;60:29–33.
   Google Scholar
• Lindegaard B, Ditlevsen S, Plomgaard P, et al. Acute reduction of lipolysis reduces adiponectin and IL-18: evidence from an intervention study with acipimox and insulin. Diabetologia. 2013;56:2034–2043.
   PubMed Web of Science ®Google Scholar
• Herman WA, Lacka K, Kaufman E, et al. The associations between iL-18 serum levels and the prevalence of metabolic syndrome in Polish men over the age of 40 according to other selected inflammatory indices and androgens: comparison of NCEP with IDF criteria. Exp Clin Endocrinol Diabetes. 2011;119:423–430.
   PubMed Web of Science ®Google Scholar
• Esposito K, Marfella R, Giugliano D. Plasma interleukin-18 concentrations are elevated in type 2 diabetes. Diabetes Care. 2004;27:272
   PubMed Web of Science ®Google Scholar
• Thorand B, Kolb H, Baumert J, et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984–2002. Diabetes. 2005;54:2932–2938.
   PubMed Web of Science ®Google Scholar
• Suchanek H, Mysliwska J, Siebert J, et al. High serum interleukin-18 concentrations in patients with coronary artery disease and type 2 diabetes mellitus. Eur Cytokine Netw. 2005;16:177–185.
   PubMed Web of Science ®Google Scholar
• Araki S, Haneda M, Koya D, et al. Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study. Diabetologia. 2007;50:867–873.
   PubMed Web of Science ®Google Scholar
• Nagai N, Ito Y, Okamoto N, et al. Changes in interleukin 18 in the retinas of Otsuka long-evans Tokushima fatty rats, a model of human type 2 diabetes. J Oleo Sci. 2013;62:513–523.
   PubMed Web of Science ®Google Scholar
• Negi SI, Pankow JS, Fernstrom K, et al. Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care. 2012;35:1513–1518.
   PubMed Web of Science ®Google Scholar
• Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067–2072.
   PubMed Web of Science ®Google Scholar
• Bloch-Damti A, Bashan N. Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxid Redox Signal. 2005;7:1553–1567.
   PubMed Web of Science ®Google Scholar
• Dezayee ZM. Interleukin-18 can predict pre-clinical atherosclerosis and poor glycemic control in type 2 diabetes mellitus. Int J Appl Basic Med Res. 2011;1:109–112.
   PubMedGoogle Scholar
• Ma Z, Li W, Yoshiya S, et al. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18. Clin Cancer Res. 2016;22:2969–2980.
   PubMed Web of Science ®Google Scholar
• Salman M, Yassin DJ, Shoukfeh H, et al. Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. Aging Male. 2017;20:45–48.
   PubMed Web of Science ®Google Scholar
• Opstad TB, Pettersen AA, Arnesen H, et al. Circulating levels of IL-18 are significantly influenced by the IL-18 + 183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study. Cardiovasc Diabetol. 2011;10:110.
   PubMed Web of Science ®Google Scholar
• Aoyama M, Kotani J, Usami M. Gender difference in granulocyte dynamics and apoptosis and the role of IL-18 during endotoxin-induced systemic inflammation. Shock. 2009;32:401–409.
   PubMed Web of Science ®Google Scholar